Who Is Not a Candidate? A Full Review of GLP-1 Contraindications

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed care for type 2 diabetes and weight management. Medications such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) and tirzepatide (Mounjaro) can improve blood sugar control and promote weight loss. However, not everyone is a safe candidate. This GLP-1 contraindications overview explains who should generally avoid—or use with extreme caution—these therapies.

Absolute Contraindications

Absolute contraindications are conditions in which a GLP-1 RA should not be started under any circumstances due to high risk of serious harm.

• Personal or family history of medullary thyroid carcinoma (MTC)
  • Animal studies suggest GLP-1 RAs may promote C-cell tumors.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Inherited disorder predisposing to MTC and other tumors.
• Known hypersensitivity to the drug or excipients
  • Severe allergic reactions, such as anaphylaxis.
• Pregnancy and breastfeeding
  • Safety during pregnancy or lactation has not been established.

If any of the above apply, GLP-1 RAs are contraindicated.

Relative Contraindications

Relative contraindications call for careful evaluation of risks versus benefits and may require dose adjustments or extra monitoring.

• History of pancreatitis
  • Some reports link GLP-1 RAs to acute pancreatitis, though causality is unclear.
• Severe gastrointestinal (GI) disease
  • Gastroparesis, chronic nausea or vomiting may worsen.
• Severe renal impairment
  • Risk of dehydration and acute kidney injury from GI side effects.
• Diabetic retinopathy
  • Rapid blood sugar drops can transiently worsen retinal disease.
• Type 1 diabetes
  • Inadequate insulin production makes GLP-1 RAs ineffective.
• Children and adolescents
  • Limited safety data; some agents are not approved under 18.
• History of major psychiatric illness
  • Risk of altered appetite/weight changes may impact mood disorders.

In these groups, close collaboration with a healthcare professional is essential.

Special Populations

1. Pancreatitis or High Pancreatic Risk

• If you have had acute or chronic pancreatitis, discuss alternatives.
• Monitor for abdominal pain, nausea, vomiting.
• Consider imaging or enzyme tests if symptoms arise.

2. Severe GI Disorders

• Gastroparesis (delayed stomach emptying) and inflammatory bowel disease can worsen.
• If you develop persistent nausea, bloating or vomiting, stop the GLP-1 RA and seek care.
• Small, frequent meals and antiemetics may help if mild GI upset occurs.

3. Renal Impairment

• Moderate to severe kidney disease (eGFR <30 mL/min) raises risk of dehydration and acute injury.
• Initiate at a lower dose and monitor renal function regularly.
• Encourage adequate fluid intake.

4. Thyroid C-Cell Tumor Risk

• All patients starting GLP-1 RAs should have no personal or family history of MTC or MEN2.
• Routine calcitonin monitoring is not generally recommended but may be considered if suspicion arises.

5. Diabetic Retinopathy

• If you have proliferative retinopathy or macular edema, inform your eye specialist.
• Ensure scheduled retinal exams; adjust treatment if retinopathy worsens with rapid glycemic improvement.

6. Pregnancy, Breastfeeding and Fertility

• GLP-1 RAs are not recommended during pregnancy or lactation due to unknown fetal/milk transfer risks.
• Women planning pregnancy should discuss stopping and transitioning to insulin if needed.
• Breastfeeding mothers should avoid GLP-1 therapy until more safety data emerge.

Key Drug-Specific Notes

• Semaglutide (injectable and oral)
  Potent appetite suppressant; higher rates of GI side effects.
• Liraglutide
  Lower GI side effects than semaglutide; daily injection required.
• Dulaglutide & Exenatide
  Weekly injections; vary in GI tolerability.
• Tirzepatide
  Dual GIP/GLP-1 action; strong efficacy but also potent GI effects.

Always follow the specific prescribing information for dosing, storage and administration.

Monitoring and Safety Tips

• Start at the lowest recommended dose and titrate slowly.
• Educate patients on recognizing:
  • Persistent severe nausea or vomiting
  • Signs of pancreatitis (severe abdominal pain)
  • Unusual thyroid or neck swelling
  • Vision changes
• Maintain regular labs: renal function, pancreatic enzymes and thyroid markers if indicated.
• Coordinate care with endocrinologists, gastroenterologists and ophthalmologists as needed.

When to Reconsider or Stop Therapy

• Development of acute pancreatitis or severe GI reactions
• New diagnosis of medullary thyroid carcinoma or MEN2
• Worsening renal function despite dose adjustments
• Pregnancy confirmed during therapy
• Intractable nausea, vomiting or dehydration

Next Steps and Resources

If you're unsure whether you're a good candidate or if you're experiencing concerning symptoms, start by using this free Medically approved LLM Symptom Checker Chat Bot to get personalized guidance on your symptoms and understand whether you need immediate care.

Always discuss any major decisions or worrisome signs with your healthcare provider. If you experience life-threatening or serious symptoms—severe abdominal pain, signs of allergic reaction, extreme dehydration—seek immediate medical attention or call emergency services.

Speak to a doctor before starting or stopping any medication. Your provider will tailor treatment based on your unique health history, risks and goals.

---

GLP-1 receptor agonists offer powerful benefits for many, but they're not suitable for everyone. This GLP-1 contraindications overview highlights the key scenarios where these drugs may pose more risk than reward. Careful screening, patient education and ongoing monitoring ensure the safest and most effective outcomes.